NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 52 filers reported holding NEUROCRINE BIOSCIENCES INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $405,000 | +5.2% | 309,000 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $385,000 | -6.1% | 309,000 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $410,000 | -0.7% | 309,000 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $413,000 | -0.5% | 309,000 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $415,000 | +24.6% | 309,000 | +28.2% | 0.00% | 0.0% |
Q4 2020 | $333,000 | +51.4% | 241,000 | +50.6% | 0.00% | 0.0% |
Q3 2020 | $220,000 | -17.3% | 160,000 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $266,000 | +29.8% | 160,000 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $205,000 | -16.3% | 160,000 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $245,000 | +11.9% | 160,000 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $219,000 | +4.3% | 160,000 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $210,000 | -53.0% | 160,000 | -51.7% | 0.00% | -50.0% |
Q1 2019 | $447,000 | +120.2% | 331,000 | +178.2% | 0.00% | +100.0% |
Q4 2018 | $203,000 | 0.0% | 119,000 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $203,000 | -31.4% | 119,000 | -42.0% | 0.00% | 0.0% |
Q2 2018 | $296,000 | – | 205,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Myriad Asset Management Ltd. | 17,500,000 | $29,890,000 | 4.31% |
SSI INVESTMENT MANAGEMENT LLC | 8,987,000 | $15,319,000 | 1.18% |
CSS LLC/IL | 14,955,000 | $25,561,000 | 1.09% |
SHENKMAN CAPITAL MANAGEMENT INC | 3,983,000 | $6,799,000 | 0.82% |
Verition Fund Management LLC | 6,425,000 | $10,968,000 | 0.39% |
ADVENT CAPITAL MANAGEMENT /DE/ | 9,495,000 | $16,214,000 | 0.33% |
MACKAY SHIELDS LLC | 21,609,000 | $36,877,000 | 0.28% |
WOLVERINE ASSET MANAGEMENT LLC | 12,776,000 | $21,819,000 | 0.25% |
Calamos Advisors LLC | 24,100,000 | $41,405,000 | 0.23% |
OAKTREE CAPITAL MANAGEMENT LP | 8,895,000 | $15,184,000 | 0.20% |